Australia’s TGA Grants Approval to First Objective Concussion Diagnostic

Oculogica’s EyeBOX is the only objective diagnostic cleared by the US FDA and Australia TGA as an aid in diagnosis of concussion.   New York, NY- May 4, 2021—Oculogica, a medical device company and leader in concussion diagnosis and categorization, announced today the Therapeutic Goods Administration (TGA) of Australia granted approval to its EyeBOX technology. …

Australia’s TGA Grants Approval to First Objective Concussion Diagnostic Read More »

Oculogica Adds to IP Portfolio with Patent for Glaucoma

Oculogica, the leader in non-invasive assessment of concussion, announces today the granting of U.S. Patent No. 10,863,902 by the U.S. Patent and Trademark Office. This patent protects Oculogica’s method and system for assessing glaucoma in a patient using a noninvasive eye tracking system.

Oculogica Announces New Category 3 CPT Code Created by American Medical Association

Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics for brain health, announced today that the American Medical Association (AMA) has confirmed the addition of a new Category 3 CPT Code, 0X17T, Eye movement analysis test without spatial calibration, allowing clinicians to appropriately report the services related exclusively to the Oculogica EyeBOX® exam.

Scroll to Top